Plain-English translation of NCT07379918 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a long-term observational study following patients with early-stage, hormone-receptor-positive breast cancer who have undergone an Endopredict® genetic test. The test helps doctors determine your individual risk of cancer recurrence and decide whether you need chemotherapy in addition to hormone therapy. Researchers are collecting real-world data to confirm how accurate and useful this genetic test is in guiding treatment decisions for patients like you.
For many patients with early breast cancer, it's unclear whether chemotherapy will truly help prevent recurrence, or whether hormone therapy alone is enough. This study exists to gather real-world evidence showing whether the Endopredict® test reliably identifies patients who can safely avoid chemotherapy without increasing their risk of cancer coming back.
You likely qualify if…
You likely don't qualify if…
As a participant, you would not receive any new treatment — instead, researchers would collect and track your existing medical information, including your test results, tumor characteristics, and health outcomes over a 10-year period. Your doctors and the research team would follow your long-term progress through regular clinic visits and medical records to see whether the genetic test correctly predicted your recurrence risk and helped guide your treatment decisions.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
France